Colossal's New AI Tool: Scientific Breakthrough or VC Fantasy?

Colossal Biosciences is leaning heavily into the AI hype cycle to solve a fundamental problem in its business model: the scarcity of raw data. As TechCrunch first reported, the company has unveiled GenoMorph, an AI platform designed to accelerate de-extinction efforts by identifying specific genes for editing in species where genomic data is limited.

***Opinion:*** *As a skeptic of the 'moonshot' pitch, I find the technical ambition impressive, but the unit economics of de-extinction remain a black box. Colossal is effectively selling a high-concept fantasy to investors. Until we see a P&L that proves these animals can be produced at scale—or that the underlying 'programmable biology' has a repeatable commercial application—this looks less like a viable company and more like an expensive laboratory experiment.*

According to TechCrunch, the GenoMorph platform utilizes 3D morphology, developmental biology, and comparative genomics to predict genetic switches. Colossal CEO and co-founder Ben Lamm told TechCrunch that the tool is particularly vital for the dodo bird project, as the company possesses only one dodo genome compared to the 100 available for the woolly mammoth project. Lamm described the platform as a "treasure map" that allows the team to bypass exhaustive searches and focus on the genetic differences that matter. To build the system, Lamm stated the company combined genetic information and 3D skull measurements from over 70 bird species with developmental data from pigeons, ducks, quail, and chickens.

TechCrunch reports that Colossal has already identified roughly 2,300 DNA editing targets for dodo cranial facial morphology. To test these, the company is using lipid nanoparticles to deliver gene-editing tools into bird embryos, a process Lamm says avoids the need to wait for birds to reach sexual maturity through a full breeding cycle. Additionally, the company announced its Nicobar pigeon colony—the dodo's closest living relative—now consists of 36 birds, and that essential cells for sperm and eggs have been created.

While the science is speculative, the venture capital interest is concrete. TechCrunch reports that XPRIZE founder and Colossal investor Peter Diamandis has launched a new VC firm, NeoGenesis Capital. Diamandis intends to use the firm to back companies that utilize Colossal Biosciences’ programmable biology platform within the sectors of conservation, agriculture, and health.